Patents by Inventor Dulce Garrido Bubacz

Dulce Garrido Bubacz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kv2.1 antagonists
    Patent number: 6589934
    Abstract: The invention relates to methods of treatment of non insulin dependent diabetes mellitus, antagonists of the delayed rectifier potassium channel Kv2.1, methods of using and preparing the antagonists and assays for identifying such antagonists.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: July 8, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Dulce Garrido Bubacz, Iain David Dukes, Ed Williams McLean, Robert Anderson Noe, Andrew James Peat, Jerzy Ryszard Szewczyk, Stephen Andrew Thomson, Jennings Franklin Worley, III
  • Formamide compounds as therapeutic agents
    Patent number: 6329400
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: December 11, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Formamide compounds as therapeutic agents
    Patent number: 6191150
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: February 20, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, Dulce Garrido Bubacz, Joseph Howing Chan, David John Cowan, Michael David Gaul, Daryl Lynn McDougald, David Lee Musso, Michael Howard Rabinowitz, Jennifer Badiang Stanford, Robert William Wiethe
  • Opioid diarylmethylpiperazines and piperidines
    Patent number: 5854249
    Abstract: A method for the treatment or prophylaxis of one or more conditions or disorders selected from the group consisting of physiological pain, diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depressioysema, apnea, cognitive disorders and gastrointestinal disorders, comprising administration to a subject in need of such treatment or prophylaxis, of a diarylmethylpiperazine or piperidine opioid compound.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: December 29, 1998
    Assignee: Delta Pharmaceuticals, Inc.
    Inventors: Kwen-Jen Chang, Grady Evan Boswell, Dulce Garrido Bubacz, Mark Allan Collins, Ann Otstot Davis, Robert Walton McNutt, Jr.
  • Opioid diarylmethylpiperazines and piperdines
    Patent number: 5658908
    Abstract: Diarylmethylpiperazine compounds having utility as receptor-binding species, e.g., for mediating analgesia, and for combatting drug addiction, alcohol addiction, and drug overdose. The compounds may be administered orally, rectally, topically, nasally, ophthalmically, or parenterally (subcutaneously, intramuscularly, and intravenously), for veterinary and human use, and include delta receptor and mu receptor binding species.
    Type: Grant
    Filed: August 3, 1994
    Date of Patent: August 19, 1997
    Assignee: Delta Pharmaceuticals, Inc.
    Inventors: Kwen-Jen Chang, Grady Evan Boswell, Dulce Garrido Bubacz, Mark Allan Collins, Ann Otstot Davis, Robert Walton McNutt, Jr.